Last 14 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Jin Medical International Ltd.'s quarterly P/E stands at 17.7x, down 57.1% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 44.1% YoY to 20.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 16.53 | 17.66 | — | 56.04 | 84.21 | 41.20 | 7.36 | — | — | — | — | — | — |
| — | -57.1% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 0.94 | 2.05 | 2.78 | 8.13 | 14.22 | 4.77 | 1.26 | — | — | — | — | — | — |
| — | -57.1% | +120.6% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.66 | 2.99 | 3.96 | 14.75 | 22.96 | 7.61 | 2.20 | — | — | — | — | — | — |
| — | -60.7% | +80.4% | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | 53.81 | — | — | 175.45 | 4.73 | — | — | — | — | — | — |
| — | — | +1037.2% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 33.08 | 20.85 | — | 42.00 | 111.48 | 37.28 | 5.90 | — | — | — | — | — | — |
| — | -44.1% | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 50.74 | 23.51 | — | 44.05 | 122.36 | 35.88 | 6.28 | — | — | — | — | — | — |
| — | -34.5% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Jin Medical International Ltd.'s operating margin was 9.8% in Q4 2025, up 14.4 pp QoQ and down 1.6 pp YoY.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 29.2% | 33.7% | 25.6% | 44.9% | 36.0% | 34.0% | 35.4% | 32.4% | 33.9% | 25.9% | 38.3% | 32.2% | 36.2% |
| — | -0.9% | -27.6% | +38.8% | +6.0% | +31.3% | -7.5% | +0.6% | -6.3% | -27.6% | +0.9% | — | — | |
| Operating Margin | 2.9% | 9.8% | -4.6% | 18.6% | 11.6% | 11.5% | 17.3% | 11.5% | 10.7% | 6.9% | 19.6% | 13.1% | 16.4% |
| — | -14.2% | -126.6% | +62.5% | +8.4% | +64.8% | -11.7% | -12.5% | -34.4% | -66.8% | -12.3% | — | — | |
| Net Margin | 5.8% | 11.8% | -0.9% | 14.5% | 17.0% | 11.6% | 17.2% | 15.2% | 12.9% | 7.0% | 19.6% | 11.5% | 16.3% |
| — | +2.0% | -105.2% | -4.5% | +31.3% | +66.8% | -11.9% | +32.8% | -20.7% | -55.5% | -3.0% | — | — |
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.1% | 4.5% | -0.3% | 6.9% | 7.2% | 4.7% | 9.1% | 9.6% | 8.3% | 5.8% | 15.4% | 9.1% | 10.3% |
| — | -4.5% | -103.5% | -28.5% | -13.7% | -19.9% | -41.0% | +5.8% | -19.8% | -63.9% | -32.3% | — | — | |
| ROA | 2.4% | 2.5% | -0.2% | 4.3% | 4.8% | 3.5% | 6.8% | 6.9% | 5.6% | 3.4% | 8.2% | 4.8% | 5.5% |
| — | -27.8% | -102.8% | -37.5% | -13.6% | +1.5% | -16.8% | +43.8% | +1.8% | -56.3% | — | — | — | |
| ROIC | 1.2% | 2.2% | -1.1% | 6.1% | 3.8% | 4.4% | 9.9% | 7.5% | 6.9% | 5.9% | 12.8% | 7.2% | 7.2% |
| — | -50.6% | -110.6% | -18.5% | -44.4% | -25.3% | -22.5% | +3.7% | -5.0% | -57.6% | -13.9% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Jin Medical International Ltd.'s Debt/EBITDA ratio is 15.8x — elevated, raising questions about debt serviceability. The current ratio has weakened 46.8% YoY to 1.86x, tightening the short-term liquidity position. Debt/Equity has risen for 6 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.64 | 0.64 | 0.57 | 0.41 | 0.38 | 0.17 | 0.06 | — | — | — | 0.18 | 0.25 | 0.19 |
| — | +272.8% | +827.3% | — | — | — | -64.8% | — | — | — | — | — | — | |
| Debt / EBITDA | 20.27 | 15.79 | — | 4.59 | 7.37 | 3.41 | 0.77 | — | — | — | 1.14 | 1.97 | 1.73 |
| — | +362.5% | — | — | — | — | -32.3% | — | — | — | — | — | — | |
| Current Ratio | 1.86 | 1.86 | 2.11 | 2.50 | 2.58 | 3.49 | 3.89 | 3.31 | 3.06 | 2.47 | 1.93 | 1.81 | 1.91 |
| — | -46.8% | -45.7% | -24.7% | -15.7% | +41.3% | +101.5% | +82.8% | +60.0% | +34.6% | — | — | — | |
| Quick Ratio | 1.65 | 1.65 | 1.82 | 2.08 | 2.15 | 2.83 | 3.02 | 2.14 | 1.80 | 1.57 | 1.14 | 1.09 | 1.11 |
| — | -41.8% | -39.8% | -2.5% | +19.3% | +80.0% | +163.9% | +96.1% | +62.5% | +26.9% | — | — | — | |
| Interest Coverage | — | — | — | 11.20 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZJYL stock.
Jin Medical International Ltd.'s current P/E is 16.5x. The average P/E over the last 3 quarters is 52.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Jin Medical International Ltd.'s current operating margin is 2.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Jin Medical International Ltd.'s business trajectory between earnings reports.